StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
13
Publishing Date
2021 - 06 - 04
13
Sector
Health technology
8
Manufacturing
1
Tags
Acquisition
12
Acquisition corp
9
Antibody
2
Application
2
Approval
4
Awards
2
Bioscience
3
Biotech
3
Biotech-bay
4
Blood
3
Brands
2
Breast cancer
3
Cancer
12
Car-t
2
Ceo
4
China
2
Clinical-trials-phase-ii
3
Collaboration
3
Commercialization
3
Communication
2
Communications
2
Conference
23
Covid
6
Covid-19
3
Distribution
6
Drug
7
Energy
6
Ev
7
Events
5
Expansion
4
Financial results
4
Food
3
Grant
7
Granted
7
Growth
6
Iot
8
License
4
Lung cancer
4
Market
3
Media
3
Merge
4
Mobile
4
N/a
269
Nasdaq
5
Oda
4
Offering
8
Ongoing
3
Phase 1
9
Phase 2
7
Phase 3
8
Positive
6
Presentation
5
Research
12
Results
13
Risk
3
T-cell
3
Technology
12
Therapy
11
Treatment
13
Trial
10
Entities
4d pharma plc - adr
1
Abbvie inc.
1
Chimerix, inc.
2
Coherus biosciences, inc.
1
Golden arrow merger corp - class a
1
Incyte corporation
1
Intellia therapeutics, inc.
1
Marlin technology corp - class a
1
Morphosys ag
1
One equity partners open water i corp - class a
1
Pharvaris nv
1
Regeneron pharmaceuticals, inc.
1
Rubius therapeutics, inc.
1
Sorrento therapeutics, inc.
1
Surface oncology, inc.
1
Xencor, inc.
1
Symbols
ABBV
1
CHRS
1
CMRX
2
FINM
1
GAMC
1
INCY
1
LBPS
1
MOR
1
NTLA
1
OEPW
1
PHVS
1
REGN
1
RUBY
1
SRNE
1
SURF
1
XNCR
1
Exchanges
Nasdaq
13
Nyse
1
Crawled Date
2024 - 03 - 19
12
2024 - 03 - 04
13
2023 - 12 - 12
13
2023 - 12 - 06
14
2023 - 11 - 27
12
2023 - 10 - 18
12
2023 - 10 - 16
16
2023 - 10 - 04
14
2023 - 09 - 26
17
2023 - 09 - 20
12
2023 - 09 - 07
14
2023 - 06 - 26
13
2023 - 04 - 25
13
2023 - 04 - 17
14
2023 - 02 - 23
12
2023 - 01 - 30
16
2023 - 01 - 25
14
2022 - 11 - 17
12
2022 - 10 - 12
13
2022 - 09 - 14
12
2022 - 08 - 22
13
2022 - 05 - 17
13
2022 - 03 - 28
14
2022 - 01 - 24
16
2021 - 12 - 13
15
2021 - 12 - 09
12
2021 - 12 - 06
14
2021 - 11 - 29
11
2021 - 11 - 12
11
2021 - 11 - 01
12
2021 - 10 - 25
11
2021 - 10 - 19
11
2021 - 10 - 18
15
2021 - 10 - 14
12
2021 - 10 - 12
12
2021 - 10 - 07
13
2021 - 10 - 04
12
2021 - 09 - 30
11
2021 - 09 - 09
11
2021 - 09 - 07
12
2021 - 08 - 24
11
2021 - 07 - 13
11
2021 - 06 - 29
12
2021 - 06 - 28
11
2021 - 06 - 25
13
2021 - 06 - 23
14
2021 - 06 - 21
13
2021 - 06 - 11
11
2021 - 06 - 04
13
2021 - 06 - 03
12
2021 - 06 - 01
14
2021 - 05 - 21
15
2021 - 05 - 03
13
2021 - 04 - 30
11
2021 - 04 - 15
11
2021 - 03 - 22
14
2020 - 12 - 15
14
2020 - 12 - 03
11
2020 - 12 - 02
12
2020 - 12 - 01
18
Crawled Time
01:00
1
12:00
4
13:00
1
18:00
1
19:00
1
20:00
1
21:00
3
23:00
1
Source
www.4dpharmaplc.com
1
www.biospace.com
3
www.globenewswire.com
6
www.prnewswire.com
2
www.rubiustx.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Treatment
crawled date :
2021 - 06 - 04
save search
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing –
Published:
2021-06-04
(Crawled : 23:00)
- biospace.com/
CMRX
|
$0.9269
1.42%
1.4%
180K
|
Health Technology
|
-89.17%
|
O:
0.24%
H:
10.33%
C:
3.21%
food
treatment
antiviral
drug
smallpox
approval
Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants, One Equity Partners Open Water I Corp. Announces Receipt of NASDAQ Continued Listing Standard Notice
Published:
2021-06-04
(Crawled : 21:00)
- prnewswire.com
OEPW
|
$10.07
-0.1%
3.18%
|
|
Email alert
Add to watchlist
treatment
Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants, Marlin Technology Corporation Announces Receipt of NASDAQ Continued Listing Standard Notice
Published:
2021-06-04
(Crawled : 21:00)
- prnewswire.com
FINM
4
|
$10.14
0.0%
120K
|
|
Email alert
Add to watchlist
treatment
technology
Stemming from SEC Guidance Concerning Accounting Treatment of Warrants, Golden Arrow Merger Corp. Announces Receipt of Nasdaq Continued Listing Standard Notice
Published:
2021-06-04
(Crawled : 21:00)
- globenewswire.com
GAMC
|
$10.63
0.0%
110
|
|
Email alert
Add to watchlist
treatment
merge
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Published:
2021-06-04
(Crawled : 20:00)
- biospace.com/
XNCR
|
$18.35
0.77%
0.76%
480K
|
Health Technology
|
-50.23%
|
O:
0.38%
H:
1.25%
C:
-0.76%
MOR
|
News
|
$18.04
0.45%
0.44%
180K
|
Health Technology
|
-8.03%
|
O:
3.74%
H:
3.11%
C:
2.76%
INCY
|
$51.62
-0.58%
-0.58%
2.5M
|
Health Technology
|
-37.37%
|
O:
0.33%
H:
1.54%
C:
0.19%
treatment
phase 2
results
als
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
Published:
2021-06-04
(Crawled : 19:00)
- globenewswire.com
CMRX
|
$0.9269
1.42%
1.4%
180K
|
Health Technology
|
Email alert
Add to watchlist
food
treatment
drug
smallpox
approval
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
Published:
2021-06-04
(Crawled : 18:00)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.88%
|
O:
1.73%
H:
2.43%
C:
-1.58%
treatment
collaboration
cancer
research
A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers
Published:
2021-06-04
(Crawled : 13:00)
- rubiustx.com
RUBY
|
$0.057
-99.3%
760K
|
Health Technology
|
-99.77%
|
O:
0.62%
H:
3.05%
C:
1.94%
treatment
blood
phase 1
positive
rtx-321
cancer
phase 3
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
Published:
2021-06-04
(Crawled : 12:00)
- 4dpharmaplc.com
LBPS
|
$1.65
-0.61%
|
Manufacturing
|
Email alert
Add to watchlist
treatment
trial
enroll
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop
Published:
2021-06-04
(Crawled : 12:00)
- biospace.com/
PHVS
|
$21.7
3.98%
3.82%
89K
|
|
1.98%
|
O:
1.64%
H:
1.06%
C:
-1.78%
treatment
ev
Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma
Published:
2021-06-04
(Crawled : 12:00)
- globenewswire.com
SURF
|
$1.07
-0.93%
-1.41%
0
|
Health Technology
|
-88.19%
|
O:
2.76%
H:
0.64%
C:
-12.24%
treatment
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
Published:
2021-06-04
(Crawled : 12:00)
- globenewswire.com
REGN
|
News
|
$906.84
0.74%
0.74%
340K
|
Health Technology
|
78.02%
|
O:
0.38%
H:
2.12%
C:
0.85%
NTLA
|
$21.535
-1.35%
-1.37%
850K
|
Health Technology
|
-69.47%
|
O:
1.68%
H:
4.4%
C:
-0.65%
treatment
ongoing
phase 1
phase 3
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published:
2021-06-04
(Crawled : 01:00)
- globenewswire.com
ABBV
|
News
|
$169.54
0.98%
-0.91%
4.1M
|
Health Technology
|
49.62%
|
O:
0.17%
H:
0.63%
C:
-0.04%
CHRS
|
$2.19
0.46%
0.46%
810K
|
Health Technology
|
-83.28%
|
O:
7.36%
H:
1.43%
C:
-5.21%
treatment
therapy
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
M
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.